<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01437813</url>
  </required_header>
  <id_info>
    <org_study_id>GLMT13-SIL</org_study_id>
    <nct_id>NCT01437813</nct_id>
  </id_info>
  <brief_title>BIOAVAILABILITY OF Glimepiride/Extended Release Metformin (GLI/METXR): High Fat Diet Study</brief_title>
  <acronym>GLMT13</acronym>
  <official_title>Bioavailability of Glimepiride/Extended Release Metformin (4/850 mg) After a High Fat Diet, in Healthy Mexican Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Silanes S.A. de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratorios Silanes S.A. de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      The purpose of this study is to evaluate the effect of food intake in bioavailability (BA) of
      the combination Glimepiride/ extended release Metformin GLI/METXR (4/850mg) in healthy
      Mexican volunteers.

      Methods: A prospective, longitudinal, open label, non randomized study, was performed. A
      single oral dose of GLI/METXR (4/850 mg)was administered to 24 health Mexican volunteers 30
      min after a high fat meal. Blood samples were collected before the administration and 0.33,
      0.67, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6.7, 8, 10, 12, 16, 20, 24 and 30 hours
      post-administration. Plasma concentration of the drug was measured by using HPLC. Plasma
      concentration of botk drugs were measured using high-performance liquid chromatography
      (HPLC). Plasma concentration time curves were plotted for each volunteers, and
      pharmacokinetic parameters (PK) were calculated. Adverse events were determined using
      clinical and laboratory test results throughout the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Predose,0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose</time_frame>
    <description>Cmax, Area Under Curve, Tmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>0.25, 0.5, 0.75, 1, 1.5, 2, 2.5,3, 3.5, 4, 4.5, 5, 6, 7, 8, 10, 12, 16,20, 24 y 30 hours post-dose</time_frame>
    <description>Any change in health or undesirable experience in volunteers related or unrelated with the experimental drug.
Adverse events were determined using clinical and laboratory test results, throughout the study.</description>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride/extended release Metformin</intervention_name>
    <description>One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.</description>
    <other_name>GLIMETXR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Mexican volunteers, considered healthy according to standard screening
             assessments

          -  Aged between 18 and 50 years old

          -  Body mass index (BMI) was 18 to 27.5

        Exclusion Criteria:

          -  Those with a history or evidence of cardiovascular, renal, hepatic, gastrointestinal,
             neurologic, muscular, metabolic, or hematologic abnormality

          -  Any acute or chronic disease

          -  Any drug allergy and female volunteers positive to urinary pregnancy test or
             breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yamanqui Ibañez, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>INVESTIGACIÓN FARMACOLÓGICA Y BIOFARMACEUTICA.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigación Farmacológica Y Biofarmaceutica, S.A. de C.V.</name>
      <address>
        <city>México</city>
        <zip>14610</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <results_reference>
    <citation>Badian M, Korn A, Lehr KH, Malerczyk V, Waldhäusl W. Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. Int J Clin Pharmacol Ther Toxicol. 1992 Nov;30(11):481-2.</citation>
    <PMID>1490793</PMID>
  </results_reference>
  <results_reference>
    <citation>Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996 Feb 29;334(9):574-9. Review.</citation>
    <PMID>8569826</PMID>
  </results_reference>
  <results_reference>
    <citation>Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother. 1998 Oct;32(10):1044-52. Review.</citation>
    <PMID>9793597</PMID>
  </results_reference>
  <results_reference>
    <citation>Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997 Jan;102(1):99-110. Review.</citation>
    <PMID>9209206</PMID>
  </results_reference>
  <results_reference>
    <citation>DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999 Aug 17;131(4):281-303. Review.</citation>
    <PMID>10454950</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2011</study_first_posted>
  <last_update_submitted>September 20, 2011</last_update_submitted>
  <last_update_submitted_qc>September 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM2</keyword>
  <keyword>glimepiride</keyword>
  <keyword>metformin extended release</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

